MDMPEA
Aliases: Mk-71, Homarylamine, N-methylhomopiperonylamine
Categories
Summary
MDMPEA is an obscure research compound patented by Merck in 1956 as an antitussive but never marketed clinically. Animal studies showed only moderate cough-suppression efficacy. It is classified as Schedule I in the USA as a positional isomer of MDA, prohibiting all non-research human use. No verified human trials or reliable recreational reports exist in the literature. The compound undergoes rapid MAO-B metabolism, requiring extremely large doses to achieve CNS effects without enzyme inhibition.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 10-30 min | 10-20 min | 20-40 min | 30-60 min |
| Insufflated | 3-10 min | 5-15 min | 20-40 min | 30-60 min |
Tolerance
Build-up
develops rapidly after a single use (serotonergic psychedelic)
Reset
7–14 days for baseline
Effects
Positive
- Stimulation
- Physical euphoria
Negative
- Increased heart rate
- Jaw tension
- Teeth grinding
- Pupil dilation
- Vasoconstriction
- Increased perspiration
- Insomnia
- Decreased appetite
Positive
- Euphoria
- Motivation enhancement
- Wakefulness
- Increased sociability
- Cognitive euphoria
Negative
- Anxiety
- Compulsive redosing
- Increased focus
- Time distortion
- Thought acceleration
Positive
- Increased music appreciation
- Tactile enhancement
- Increased libido
- Tracers
- Color enhancement
- Pattern recognition enhancement
Negative
- Light sensitivity
- Dehydration
- Appetite suppression
- Disinhibition